VBI VACCINES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.82 CAD | -5.12% |
|
-7.66% | -10.58% |
| Apr. 16 | VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 15 | North American Morning Briefing : Stock Futures -2- | DJ |
| Sales 2024 * | 14.48M 19.84M | Sales 2025 * | 34.12M 46.76M | Capitalization | 16.78M 22.99M |
|---|---|---|---|---|---|
| Net income 2024 * | -42M -57.55M | Net income 2025 * | -25M -34.26M | EV / Sales 2024 * | 1.16 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.49 x |
| P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-1.16
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.9% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -5.12% |
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Baxter
CEO | Chief Executive Officer | 62 | 16-04-30 |
Nell Beattie
DFI | Director of Finance/CFO | 36 | 15-07-08 |
David Anderson
CTO | Chief Tech/Sci/R&D Officer | 54 | 16-05-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vaughn Himes
BRD | Director/Board Member | 63 | 23-04-23 |
Steven Gillis
CHM | Chairman | 71 | 04-12-31 |
Jeff Baxter
CEO | Chief Executive Officer | 62 | 16-04-30 |
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.59
USD
Average target price
5
USD
Spread / Average Target
+747.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.75% | 43.84B | |
| +4.64% | 41.68B | |
| +45.43% | 41.25B | |
| -11.96% | 27.04B | |
| +5.56% | 25.53B | |
| -25.35% | 18.18B | |
| -3.96% | 12.29B | |
| +25.30% | 12.29B | |
| +7.21% | 11.15B |
- Stock Market
- Equities
- VBIV Stock
- VBV Stock
